Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received Nasdaq deficiency notice for failing to maintain minimum $2.5M stockholders' equity requirement, now at risk of delisting.
Transcode Therapeutics receives Nasdaq delisting warning over equity deficiency
Filed May 22, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified RNAZ on May 19, 2026 that its stockholders' equity of $1.25M falls 50% short of the $2.5M minimum required for continued listing on Nasdaq Capital Market.
Item 3.01 verify on EDGAR → -
high
Company has until July 3, 2026 (45 days) to submit a compliance plan. If accepted, Nasdaq may grant up to 180 additional days to regain compliance through equity raises, improved operations, or other measures.
Item 3.01 verify on EDGAR → -
high
Company warns Nasdaq may reject its compliance plan, and even if accepted, it may be unable to restore required equity levels during the extension period.
Item 3.01 verify on EDGAR → -
high
Delisting would materially harm the company's operations, reputation, and share value. The deficiency notice has no immediate effect on current listing status.
Item 3.01 verify on EDGAR →
Summary
Transcode Therapeutics disclosed it received a deficiency letter from Nasdaq on May 19, 2026, warning that the company's stockholders' equity has fallen to $1.25 million—roughly half the $2.5 million minimum required to remain listed on the Nasdaq Capital Market. This follows the company's Q1 2026 quarterly report, which revealed the equity shortfall.
While the notice doesn't trigger immediate delisting, it puts the company on a compliance clock. The company has 45 days to submit a plan demonstrating how it will restore compliance, potentially through equity financing, operational improvements, or shareholder actions. If Nasdaq accepts the plan, the company could receive up to 180 additional days to execute.
However, management explicitly cautioned that Nasdaq may reject the plan outright, and even with approval, success is uncertain. Retail investors should monitor whether RNAZ files a compliance plan by the July 3 deadline and watch for any announcements of equity raises or strategic changes. Delisting would severely impact liquidity and share value, making the next 45 days critical for the company's future as a publicly traded entity.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 24, 2026 · How we verify